**Stem Cell Transplant-Supportive Care**

- **TMA**
  - IRB 22209: A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 month to < 18 years of age) with Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplantation (HSCT)

- **VOD**
  - IRB 16498: Phase 3 comparing Defibrotide vs SOC for VOD prevention in adults and pediatrics undergoing HSCT

- **CRS**
  - IRB 20389: A Phase 2, Single-Arm, Open-Label Study of Itacitinib, for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

- **GVHD**
  - **Acute GVHD**
    - IRB 19856: EQUATE A Study to Evaluate the Safety, Tolerability, PK, PD and Clinical Activity of EQ001 in Subjects with aGVHD
  - **Intestinal aGVHD**
    - IRB 19768: BMT CTN 1703/1801: Comparing two treatments for aGVHD (Tac/MTX) vs Post transplant (PTCy/Tac/MMF) in setting of reduced intensity conditioning allo PBSC transplant.
    - IRB 19914: GRAPHITE Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation

**Key**

- Open for Enrollment
- In Development
- Enrollment on Hold

10/29/2020